Abstract：Objective To investigate the level of IgG antibody to varicella in the healthy population aged 1-19 years in Harbin, China. Methods Random sampling was performed to select 1203 healthy individuals aged 1-19 years in Harbin. According to age, they were divided into ≥ 1 years group (n=240), ≥ 4 years group (n=396), ≥ 7 years group (n=364) and 14-19 years group (n=203). Enzyme-linked immunosorbent assay was used to measure the concentration of varicella-zoster virus (VZV)-IgG antibody in serum, and a concentration of VZV-IgG antibody of ≥ 100 mIU/mL was considered positive, suggesting that the subject had the ability to resist VZV infection. Results The overall positive rate of VZV-IgG antibody was 71.49% (860/1203), and the concentration of VZV-IgG antibody was 447±17 mIU/mL. The concentration of VZV-IgG antibody tended to increase with age (P < 0.05). The positive rate of VZV-IgG antibody in the urban population was significantly higher than that in the rural population (P < 0.05). There was significant difference in the positive rate of VZV-IgG antibody between the populations with different doses of varicella vaccination (P < 0.05), and the population with 2 doses of vaccination had the highest positive rate of VZV-IgG antibody. There was a signifcant difference in the concentration of VZV-IgG antibody between the populations with different medical histories (P < 0.05), and the population with a past history of varicella had the highest concentration. Conclusions Among the healthy population aged 1-19 years in Harbin, there is a signifcant difference in the level of VZV-IgG antibody between the urban and rural populations, as well as between different age groups. Varicella vaccination should be strengthened in areas with a low vaccination rate and the population aged <14 years.
LI Xi-Kun,GAO Xiao-Li,LI Yan et al. Seroepidemiology of varicella among the healthy population aged 1-19 years in Harbin, China[J]. CJCP, 2019, 21(3): 203-207.
Kattan JA, Sosa LE, Bohnwagner HD, et al. Impact of 2-dose vaccination on varicella epidemiology:connecticut-2005-2008[J]. J Infect Dis, 2011, 203(4):509-512.
[11]
Bialek SR, Perella D, Zhang J, et al. Impact of a routine twodose varicella vaccination program on varicella epidemiology[J]. Pediatrics, 2013, 132(5):e1134-e1140.
[12]
Deng X, Xu W, Yan R, et al. Immunogenicity and safety of different schedules of 2-dose varicella vaccination in China[J]. Hum Vaccin Immunother, 2016, 12(12):3113-3117.
